Last reviewed · How we verify

NCT05654012

Migraine in Adolescents

Recruiting now NA Last updated 13 August 2025
What this trial tests

NA trial testing MRI in Migraine in 250 participants. Currently enrolling.

Timeline
1 June 2023
Primary endpoint
15 March 2028
15 March 2030

Quick facts

Lead sponsorWashington University School of Medicine
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment250
Start date1 June 2023
Primary completion15 March 2028
Estimated completion15 March 2030
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Washington University School of Medicine

Who can join

Adults 10 to 13, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim 1. To identify psychophysical and neural factors predicting migraine onset in adolescents Aim 2a. To determine hormonal, psychophysical, and neural changes associated with migraine onset. Aim 2b. To identify the temporal relationships between hormonal, psychophysical, and neural changes preceding vs. following migraine onset. Aim 3. To identify psychophysical and neural factors predicting migraine prognosis in adolescents with migraine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

Other recruiting trials for Migraine

Currently open trials in the same condition.

Other Washington University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05654012.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing